NASDAQ:APRE
Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. reported net income of −$12.6M in fiscal 2025. The diluted share count rose 18.7%.Summary generated from Aprea Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−79.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+18.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −37 | −113 | −15 | −14 | −13 |
| Net income | −37 | −113 | −14 | −13 | −13 |
| Free cash flow | n/a | n/a | −12 | −14 | n/a |
Recent filings
- 8-KOther events
Aug 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 8-KNotice of delisting or listing-rule failure
Jul 23, 2026 - 4Insider transaction report
Jun 17, 2026 - 4Insider transaction report
Jun 17, 2026 - 8-KResults of a shareholder vote
Jun 17, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026